for the elimination of TB in the United States, but treatment is often not completed. Little is known about patients' reasons for not completing treatment. We hypothesized that certain health beliefs, lifestyle, and clinic-and regimen-related barriers to provision of care could predict non-completion of LTBI treatment. Methods: We administered a survey in English, Chinese, or Spanish to patients with LTBI at the first TB clinic visit. Using 2 and logistic regression analysis, we assessed demographics, TB risk factors, and survey responses as predictors of non-completion of 6 mo of isoniazid. Results: 217 patients, 90% foreign-born, completed the survey, and 28.6% of which finished at least 6 mo of isoniazid under usual clinic conditions. Multivariate analysis identified two independent predictors of non-completion: low risk perception of progressing to active TB without LTBI treatment (odds ratio 
METHODS

Human Studies Approval
The Institutional Review Board of Boston University Medical Campus approved this study and the surveys employed. Participation in the study was voluntary and not linked to treatment.
TB Clinic Usual Procedures
The study setting was a Boston, MA academic medical center's TB clinic. TB physicians and nurses provided TB screening, verbal and written patient education, including treatment risks and benefits (using interpreters as needed), and treatment of LTBI (1) . Baseline serum transaminases were determined in all patients. An initial visit for usual medical care, including time in the clinic, Radiology, Pharmacy, and the Clinical Laboratory, typically lasted approximately 3 to 4 h. At follow-up visits with a nurse, patients were clinically assessed for toxicity and given a 1-mo medication refill, as well as additional education. These visits usually lasted between 30 and 60 min. Serum transaminases were monitored periodically in those at increased risk for isoniazidinduced hepatitis and in those over 35 yr of age. Patients referred from specific neighborhood health centers returned there to nurse-staffed TB follow-up clinics by pre-arrangement. While primary care physicians may have provided initial referrals, they were generally not involved in treatment of LTBI within this system.
Study Enrollment
Individuals 18 or more years of age prescribed at least 6 mo of daily isoniazid only for LTBI, and who spoke English, Spanish, or Chinese, were included in the study. Patients were excluded if they were prescribed medication other than isoniazid for treatment of LTBI, had treatment delayed, or were suspected to have or had TB disease. From July 14, 2002 to September 28, 2003, 217 subjects were voluntarily enrolled, with a refusal rate of eligible patients of approximately 30%.
Survey Administration
The survey was pilot-tested before the study, measured 4.0 on the Microsoft (Redmond, WA) Word Flesch-Kincaid English readability scale, which uses the formula (0.39) (total words/total sentences) ϩ 11.8 (total syllables/total words) Ϫ 15.59 to yield a number corresponding to a United States educational grade level. The survey was also translated into Chinese and Spanish. During the enrollment period, eligible patients were approached after the initial TB clinic evaluation and patient education had been concluded. There was no time limit in which to complete the written survey, but typically respondents were finished within 10 min. Answers were kept confidential from clinic staff.
Data Analysis
We used 2 analysis to determine significance of variables relative to the primary study endpoint, completion of 6 mo of isoniazid within 9 mo, using the EpiInfo, July 2002 (CDC, Atlanta, GA) statistical program. For multivariate regression analysis, the adjusted relative risks of completion were estimated using a log-binomial model with the GENMOD procedure in SAS version 9.1 (Cary, NC).
RESULTS
Respondent Demographics and TB Risk Factors
Surveys were completed by a total of 217 individuals: 148 in English, 22 in Spanish, and 47 in Chinese. The respondents were 90% foreign-born and included a substantial proportion of racial minorities (Table 1 ). There were more women among survey participants (54.4%, versus 44.2% men). A majority of participants were under the age of 35 (52%), with a median age of 34 yr. Participant demographics were similar to those of patients with LTBI who were offered treatment at this clinic (4). The most common TB risk factor was foreign-birth in a TB endemic country. Approximately one third of participants received their follow-up at neighborhood health centers.
Completion of LTBI Treatment
A total of 29.0% completed at least 6 mo of isoniazid, with 19.4% completing the full 9-mo course and 9.2% completing between 6 and 9 mo of treatment. Nearly two-thirds (65.9%) of the participants self-discontinued treatment either by declaration or by not returning to the clinic within 3 mo. Another 5.3% had treatment discontinued by a TB provider due to adverse events, including itching, rash, fatigue, malaise, headache, dizziness, nausea, abdominal discomfort, and diarrhea.
Predictors of LTBI Treatment Non-Completion
Demographic and TB risk factors did not predict failure to complete treatment of LTBI. The completion rates by survey language were not significantly different.
Regimen and Clinic-related Barriers to Care
Concern about venipuncture, which approximately half of respondents either did not want or were unsure if they wanted, was a significant predictor of treatment . This view alone accounted for 37% of noncompleters and was a shared predictor among 18% of all noncompleters. The majority of respondents felt that they were not infected with TB, and believed that BCG vaccine would prevent the development of TB, but these views did not predict failure to complete treatment. Reluctance to have venipuncture, and perception of low TB risk, as both independent and shared predictors, accounted for 75% of non-completers.
DISCUSSION
From a broad array of patients' health-related concerns, we identified two predictors of non-completion of 6 mo of isoniazid for treatment of LTBI by multivariate analysis, which together accounted for 75% of non-completers. Patients who perceived a low risk of progressing from LTBI to TB disease were significantly less likely to complete 6 mo of isoniazid. Patients with LTBI may perceive the threat, or severity of illness, from TB disease as potentially high, but their risk of disease incidence as low (5) . Low risk perception alone was a predictor of noncompletion among 37% of non-completers. This view is likely related to the finding that only 25% of our survey participants (Table 3) unequivocally accepted the diagnosis of LTBI. Non-acceptance of LTBI diagnosis may also reflect fear of therapeutic consequences: adverse effects, follow-up visits, hidden costs, or stigma (6) (7) (8) . BCG vaccination, likely received by the majority of our foreign-born study population, is often thought to cause or confound a positive tuberculin skin test (TST) result (8, 9) , although considerable epidemiologic evidence is available to enhance the interpretation of TST results in those vaccinated (1, (9) (10) (11) (12) . Furthermore, only 6.3% of survey participants categorically doubted the protective efficacy of BCG (Table 3) , likely further contributing to the perception of low TB disease risk. Patients who perceive low risk of progressing to TB disease are likely to see little benefit in LTBI treatment.
The most significant patient concern associated with LTBI treatment was reluctance to have venipuncture, expressed by approximately half of the survey participants. This alone was a predictor of non-completion in 20% of non-completers . This view was expressed before actually having venipuncture, which was performed in the Clinical Laboratory at a separate location. Venipuncture seems to have been a greater issue for patients than concern about isoniazid toxicity, which, although held by the majority of survey participants, was not associated with failure to complete treatment (Table 3) . Historically, a significant proportion of our TB clinic patients have been considered at risk for isoniazid hepatotoxicity, leading to the transaminasemonitoring regime described. Current CDC/ATS recommendations suggest that clinical rather than biochemical monitoring may be employed in most patients without risk factors for hepatotoxicity undergoing LTBI treatment (1). This practice, rather than a wider-ranging biochemical monitoring policy, may enhance adherence to treatment of LTBI.
There were several potential limitations to our study. Other reasons for failure to complete may have emerged after treatment initiation and were not detected in this study. Among those who did not return for follow-up visits, there might have been some with adverse events associated with non-adherence to treatment of LTBI (8, 14, 15) . The threshold for stopping isoniazid due to adverse events is likely to differ between providers and patients. Adverse events have been reported to occur in 14 to 18% (14, 16) , but in our study were relatively infrequent and rarely treatment limiting. Patient education may have varied among multiple clinic providers. Three languages were used for the performance of this study, with small accrual in two of the three groups. A larger study may have permitted the identification of language group-specific risks for non-completion. While some studies have found demographic associations (8, 14) with failure to complete isoniazid LTBI treatment, we did not, and this appears to be an inconsistent finding (1) . We have shown that at the first clinic visit patients have specific views regarding the risks, inconveniences, and benefits of LTBI treatment, which are associated with treatment non-adherence. Further studies are needed to determine whether the identified predictors can be generalized, or if others emerge. The overall treatment completion rate was low in this study and was no better for the highest TB risk groups, although similar rates have been reported elsewhere (2, 8, 14, 17, 18 ). Efforts to treat LTBI are more likely to succeed in patients who perceive a greater risk from TB than the risks and inconveniences of the treatment regimen, necessitating lucid LTBI patient education addressing these concerns. Our findings also reinforce current recommendations to target individuals at high risk of TB for testing and treatment (1) . Improved diagnostic tests are now becoming available, which can more accurately draw a distinction between BCG-vaccinated individuals and TB-infected individuals, for example, such as assays of in vitro IFN-␥ release in response to Mycobacterium tuberculosis-specific antigens (19) . Such measures and eventually shorter treatment regimens will likely improve LTBI treatment acceptance and adherence. Nevertheless, since many patients fail to return for even the first followup visit, it is critical to understand and address patient concerns and beliefs at the outset, even before the first brief TB clinic visit. It may be helpful to promulgate a message of greater benefit than risk in LTBI treatment to communities with high proportions of those at greatest risk from this disease and to their health providers.
TABLE 3. GENERAL AND TB HEALTH BELIEFS AND LIFESTYLE ISSUES AS POTENTIAL BARRIERS TO TREATMENT OF LATENT TUBERCULOSIS INFECTION
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